For example, studies have demonstrated the mechanisms of acquired resistance to 1st generation TKIs in NSCLC patients with a positive EGFR mutation, including EGFRT790M mutation, MET amplification, HER-2 mutation, HGF over-expression, etc. (31). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.